Cross-sectional and longitudinal analysis of cancer vaccination trials registered on the US Clinical Trials Database demonstrates paucity of immunological trial endpoints and decline in registration since 2008 | Zendy

Tobias Janowitz | Zendy; Liangjian Lu | Zendy; Haixi Yan | Zendy; Vijay Shyam-Sundar | Zendy

Open Access

Cross-sectional and longitudinal analysis of cancer vaccination trials registered on the US Clinical Trials Database demonstrates paucity of immunological trial endpoints and decline in registration since 2008

Author(s) -

Tobias Janowitz,

Liangjian Lu,

Haixi Yan,

Vijay Shyam-Sundar

Publication year - 2014

Publication title -

drug design development and therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.964

H-Index - 64

ISSN - 1177-8881

DOI - 10.2147/dddt.s65963

Subject(s) - clinical trial , medicine , vaccination , cancer , cancer vaccine , clinical endpoint , oncology , vaccine trial , adjuvant , breast cancer , disease , cancer immunotherapy , immunotherapy , immunology

Cancer vaccination has been researched as a means of treating and preventing cancer, but successful translational efforts yielding clinical therapeutics have been limited. Numerous reasons have been offered in explanation, pertaining both to the vaccine formulation, and the clinical trial methodology used. This study aims to characterize the tumor vaccine clinical trial landscape quantitatively, and explore the possible validity of the offered explanations including the translational obstacles posed by the current common endpoints.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research